|
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Merck |
Travel, Accommodations, Expenses - Celgene; Novartis; Roche/Genentech |
|
|
Travel, Accommodations, Expenses - AstraZeneca; Pharmamar-zeltia; Roche/Genentech |
|
|
Honoraria - AstraZeneca; Celgene; Eisai; Novartis |
Consulting or Advisory Role - AstraZeneca; Celgene; Novartis |
Travel, Accommodations, Expenses - Eisai; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Eisai |
Speakers' Bureau - Celgene; Eisai; Novartis |
Research Funding - AstraZeneca; Bayer; Macrogenics; Pfizer; Roche |
|
|
Consulting or Advisory Role - Otsuka |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Macrogenics; Merck; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Novartis; Roche |